Nilotinib - Differentiating the Hope from the Hype.
Richard K Wyse1, Patrik Brundin2, Todd B Sherer3
1The Cure Parkinson's Trust, London, UK.
Journal of Parkinson'S Disease
|July 20, 2016
Summary
Nilotinib, a leukemia drug, was tested in Parkinson's disease and Dementia with Lewy Bodies patients. While potentially safe and showing minor benefits, larger studies are needed to confirm efficacy and rule out placebo effects.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB) are alpha-synucleinopathies.
- Current treatments for PD and DLB have limited efficacy.
- Nilotinib is a tyrosine kinase inhibitor used for leukemia treatment.
Purpose of the Study:
- To evaluate the safety and tolerability of Nilotinib in patients with advanced PD or DLB.
- To explore potential therapeutic benefits of Nilotinib on motor and cognitive functions in these neurodegenerative diseases.
Main Methods:
- A safety trial involving a small group of patients with advanced PD or DLB.
- Administration of Nilotinib at 150 mg or 300 mg daily for 24 weeks.
- Clinical and biochemical assessments of safety and efficacy outcomes.
Main Results:
- Nilotinib was generally found to be safe and tolerated, despite some side effects.
- Preliminary efficacy signals suggested possible benefits in motor and cognitive outcomes.
- The study was limited by a small sample size and lack of a control group, precluding definitive conclusions.
Conclusions:
- Further rigorous clinical trials are necessary to establish the definitive safety and efficacy of Nilotinib for PD and DLB.
- The potential role of Nilotinib in treating alpha-synucleinopathies requires extensive investigation.
- Future research should focus on larger, placebo-controlled studies to validate these preliminary findings.
Related Concept Videos
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
620
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
620
02:34Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
10.0K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.0K
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
57
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
57